Orbital™ DPI (Dry Powder Inhaler)

APF  Futurity™ is our first completely recyclable metal-free nasal spray pump, developed to deliver preservative-free multi-dose nasal saline and comparable OTC formulations.

APF  Futurity™ has been certified for complete recyclability by cyclosHTP (GER, NL, IRE) and ac...

The Nasal drug delivery market is experiencing high growth and scientific developments, providing a non-invasive route for systemic and CNS therapies. Innovations in device design, formulation science, and targeting strategies are improving bioavailability, patient usability, and therapeutic precision. Direct to CNS delivery and the development pathway bring together patients, formulation, and device to treat unmet market needs. This session explores the latest scientific breakthroughs, device-formulation integration, and translational strategies that are shaping the future of nasal drug delivery and expanding its potential across therapeutic areas.

Motivated by new regulations such as the EU Package and Packaging Waste Regulation (PPWR) and PFAS restriction project from the ECHA, the pharmaceutical industry is undergoing a major transformation. Many of these regulations include guidelines and mandates on the design, size, weight, recyclability, and materials used within product packaging and encourage the integration of circular economy principles. Aptar Pharma is committed to leading the shift towards a more circular flow of materials and resources, moving beyond the traditional “make, use, dispose” model. In this presentation, we’ll illustrate how Aptar Pharma Injectables helps pharmaceutical companies meet regulatory needs and sustainability goals, while setting new industry benchmarks.
Key initiatives include: More energy-efficient manufacturing process, utilizing renewable energy Waste reduction and recycling strategies within our operations Life cycle assessment tools to evaluate environmental impact Development of more sustainable packaging using innovative materials These efforts support compliance, improve operational efficiency, and promote better outcomes for both patients and the planet.

Aptar Pharma's presentation entitled " A broad range of advanced delivery platforms " explores the current extensive portfolio of high-quality OIDP (Orally Inhaled Drug Products) delivery devices. The presentation also highlights Aptar Pharma's comprehensive services which support respiratory drug development, including device selection, formulation development, analytical methods, and regulatory support. This discussion aims to showcase Aptar Pharma's latest advancements in inhalation technology, emphasizing their commitment to improving patient care through innovative drug delivery systems. Platforms available through Aptar now include the Orbital high payload DPI, Cambridge Health Innovations’ high efficiency Quattrii DPI and Pulmotree’s high end Vibrating Mesh Non-Propellant Liquid Inhaler Kolibri™.

Aptar Pharma's presentation entitled "Innovations in Inhalation" explores the current extensive portfolio of high-quality OINDP (Orally Inhaled and Nasal Drug Products) delivery devices. The presentation also highlights Aptar Pharma's comprehensive services which support respiratory drug development, including device selection, formulation development, analytical methods, and regulatory support. A key focus of the talk is the introduction of Orbital, an innovative high payload DPI system designed to enhance drug delivery efficiency and patient compliance. This discussion aims to showcase Aptar Pharma's latest advancements in inhalation technology, emphasizing their commitment to improving patient care through innovative drug delivery systems.

Big Pharma reports that up to over 90% of their CO2 emissions are scope 3. This is not only a huge burden but also the most difficult part to influence for pharmaceutical industry. However, there are ways to manage and collaborate in the industry. Christophe Marie from Aptar Group will highlight how Aptar implemented specific targets with partners and suppliers to tackle the scope 3 challenge, coming from a consumer market perspective, extrapolating into the pharmaceutical business. Also, when talking about products we are increasingly facing requests to minimize our CO2 footprint in Pharma. A great example for collaborative approaches helping to de-risk and accelerate our clients’ low GWP pressurized Metered Dose Inhaler (pMDI) programs will be illustrated by Chris Baron, based on the transition of the current pMDIs to alternative low GWP propellant technologies. Join Christophe Marie and Chris Baron at CPHI to learn how Aptar Pharma supports more sustainable product